Treatment Information

Back

Melanoma treatment details. Biologic therapy.

Vanderbilt-Ingram Cancer Center, Nashville, TN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Nashville, TN
Treatments:Biologic therapyHospital:Vanderbilt-Ingram Cancer Center
Drugs:Journal:Link
Date:Feb 2012

Description:

Patients:
This phase 2 study involved 132 previously treated advanced metastatic melanoma patients who have a BRAF V600-mutation in the cancer cells. The median patient age was 51.5 years and 61% were male.

Treatment:
Patients were treated with the biologic therapy agent vemurafenib, which is a kinase inhibitor specific to a mutation in the protein called BRAF V600E.

Toxicities:
There was one reported treatment-related death due to kidney failure. Joint pain, rash, fatigue, and alopecia were also reported.

Results:
The median overall survival was 15.9 months.

Support:
This study was supported by the pharmaceutical company Hoffmann-LaRoche.

Correspondence: Dr. Jeffrey A. Sosman; email: [email protected]



Back